Exabis Library
Welcome to the e-CCO Library!
P071: Cancer preventive effect of recombinant TRAIL by ablation of oncogenic inflammation in colitis-associated cancer rather than anticancer effect
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P071: Crohn’s Disease is associated with elevated levels of the pro-inflammatory CXCR3 ligands (CXCL9, 10 and 11) with an associated reduction in Paneth cell derived antimicrobial peptides in ex-vivo ileal biopsies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P071: Improvement of experimental mouse models in inflammatory bowel diseases using flexible video endoscopic colon evaluation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P071: Intestinal CD8+ T cell exhaustion is linked to disease activity in ulcerative colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P071: Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P071: T-cell, B-cell and monocytic infiltrations of myenteric plexus in IBD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P071: The mesentery in Crohn's disease displays mesenchymal abnormalities
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P072 Evaluation of dosing strategies of anti-TNFα monoclonal antibodies using pharmacokinetic modelling and simulation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0720: Cost-effectiveness of vedolizumab vs. ustekinumab as first-line biologic in treatment sequencing for ulcerative colitis in Canada
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0721: Anti-TNFs have similar safety profile to vedolizumab and ustekinumab as first line biologic treatment in elderly patients with Crohn’s disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0722: Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0723: Lengthening ustekinumab treatment intervals from every 8 to every 12 weeks in IBD patients in stable remission: preliminary results of a prospective observational cohort study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0724: Endoscopic and radiological outcomes of strictureplasty in patients with small bowel stricturing Crohn's disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0725: The fragility of randomized clinical trials in evaluating novel therapies for Inflammatory Bowel Disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0726: The Moderating Role of Adverse Childhood Experiences in the Relationship between Crohn's Disease Activity and the Development of PTSD Symptoms
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0727: Effectiveness and Safety of ustekinumab in the Treatment of Penetrating Crohn’s Disease: A Prospective Real-World Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0728: Interventions for ocular extraintestinal manifestations in inflammatory bowel disease: an umbrella review of systematic reviews
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0729: Comparative clinical outcomes of advanced therapy in bio-naïve versus bio-experienced patients hospitalized with Acute Severe Ulcerative Colitis: A retrospective cohort study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P072: : Circadian misalignment by simulated night shifts decreases colonoid barrier integrity in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P072: Melanocortin MC3 and MC5 receptors expression is different according to colonic disease activity in Crohn’s Disease and Ulcerative Colitis biopsies: results from an immunohistochemical observational study.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM